Atlas Trials

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Clinical trial NCT00962767 · COMPLETED

Trial details

NCT number
NCT00962767
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Leukemia, Myelocytic, Acute
Start date
2002-05-01
Primary completion
2007-12-01
Enrollment
168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.